The US Food and Drug Administration (FDA) has approved mepolizumab as a maintenance treatment for chronic obstructive ...

University of Alabama at Birmingham-led researchers have refined and validated a new framework for diagnosing chronic ...

COPD is a group of progressive lung diseases that includes emphysema and chronic bronchitis. Despite affecting an estimated 32 million people in the United States, as many as half are unaware they ...

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved ...

The COPD approval marks the fifth Nucala has received from the FDA, following green lights in severe asthma, chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis and ...

Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...

Current recommendations for diagnosis of COPD in patients with respiratory symptoms require detection of airflow obstruction ...

GSK’s Nucala receives US FDA approval for use in adults with chronic obstructive pulmonary disease: London, UK Saturday, May 24, 2025, 11:00 Hrs [IST] GSK plc announced that the ...

When you are diagnosed with COPD, it is important to remember that you are not alone. A healthcare team, which may include a ...

The FDA granted approval to mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

Women' are around 50% more likely than men to develop COPD, the umbrella term for chronic lung conditions, such as emphysema and bronchitis, even if they have never smoked or smoked much less than ...

Nucula’s new indication is as an add-on therapy for patients with COPD who also have an elevated blood eosinophil count.